Platelet Activation by a Collagen Analogue in Hemorrhagic Situations

Platelet Activation by a Collagen Analogue in Hemorrhagic Situations

Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its small size and granular, non-fibrillar presentation make it suitable for use as an injectable hemostat in patients with a hemorrhage or other emergency under antiplatelet therapy.

Inclusion Criteria:

• - person who has given their non-opposition to inclusion
• adult
• Healthy volunteers or controls (patients seen in consultation, without history of hemmorhage, etc.).

or

• patients with acute bleeding: polytraumatized, or hemorrhage or intracerebral haemorrhage, or bleeding complications at the end surgery (in particular cardiac surgery with ECMO) or
• patients with antiplatelet therapy or
• patients with thrombocytopenia/thrombopathy

Exclusion Criteria:

• protected adults (curatorship, guardianship)
• person deprived of their liberty by judicial or administrative decision
• pregnant, parturient or breastfeeding woman
• person unable to express their non-opposition
• platelet transfusion on initial management